Milvexian (BMS-986177) is an orally bioavailable, reversible, direct inhibitor of human and rabbit factor (FXIa) with Ki values of 0.11 nM and 0.38 nM, respectively.
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Pancras C Wong, et al. J Thromb Haemost. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
|Related Factor Xa Products|
MK-2060 is a monoclonal antibody with dual activity to inhibit coagulation factors XI and Xia, blocking both the activation of coagulation factor XI and the downstream activity of the activated protein. It can be used in studies related to end-stage renal disease (ESRD).
Xisomab 3G3 is a recombinant human-derived monoclonal antibody to coagulation factor XI (F11) that blocks factor XI activation mediated by factor XIIa in a concentration-dependent manner.
FXIa-IN-13 is an Factor Xa inhibitor with antithrombotic activity.
EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM.
Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.